WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, today announced the formation of the company’s Scientific and Clinical Advisory Board, comprised of experts in infectious diseases. The Advisory Board will provide strategic guidance on Entasis’ pipeline of preclinical and clinical antimicrobial candidates for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.
